Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. Traded volume was 10,401,414 million shares in the last session and the average volume of the stock remained 7.79 million shares. The beta of the stock remained 3.69. Inovio Pharmaceuticals Inc (NYSEMKT:INO) insider ownership is 0.30%.

HC Wainwright started coverage on shares of Ariad Pharmaceuticals (NASDAQ:ARIA). They issued a buy rating and a $14.00 price target on the stock. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rose 2.11 percent to $7.76 yesterday on volume of 10.13 million shares. The intra-day range of the stock was $7.58 to $7.98. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a market capitalization of $1.45 billion.

Shares of MannKind (NASDAQ:MNKD) were the recipient of some unusual options trading activity on Monday. Traders purchased 21,101 call options on the company, AnalystRatings.NET reports. This is an increase of approximately 105% compared to the average daily volume of 10,311 call options. MannKind Corporation (NASDAQ:MNKD)’s stock on Mar 25, 2014 reported a decrease of -1.86% to the closing price of $5.80. Its fifty two weeks range is $3.27 -$8.70. The total market capitalization recorded $2.19 billion. The overall volume in the last trading session was 8,752,327 million shares. In its share capital, MannKind Corporation (NASDAQ:MNKD) has 337.70 million outstanding shares.

San Diego’s Arena Pharmaceuticals (Nasdaq:ARNA), in a race to dominate the market for anti-obesity drugs, is expected to unveil an advertising campaign next month directly targeting consumers. On Tuesday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) advanced 0.50% to close the day at $6.05. Company return on investment (ROI) is -13.90% and its monthly performance is recorded as -13.69%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly revenue growth is 8.62%.